{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antidepressant+therapy",
    "query": {
      "intervention": "Antidepressant therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 516,
    "total_pages": 52,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antidepressant+therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T13:37:38.998Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00183768",
      "title": "Cognitive Behavioral Therapy Combined With Antidepressants to Reduce HIV Risk and Drug Relapse Among Depressed Intravenous Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "Depression",
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Psychopharmacology",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Butler Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 175,
      "start_date": "1999-09",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-22",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00183768"
    },
    {
      "nct_id": "NCT01555021",
      "title": "Pharmacogenomics for Antidepressant Guidance and Education",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Treatment Resistant Depression"
      ],
      "interventions": [
        {
          "name": "Genotyping assays",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2011-12",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2018-11-05",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01555021"
    },
    {
      "nct_id": "NCT01204918",
      "title": "Efficacy and Tolerability of Riluzole in Treatment Resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Riluzole",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 104,
      "start_date": "2011-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2020-03-06",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204918"
    },
    {
      "nct_id": "NCT06511908",
      "title": "Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Suicide",
        "Depressive Disorder, Treatment-Resistant",
        "Ketamine",
        "Molecular Mechanisms of Pharmacological Action",
        "Neurotransmitter Agents",
        "Excitatory Amino Acid Agents",
        "Physiological Effects of Drugs",
        "Depressive Disorder, Major",
        "Depressive Disorder",
        "Depression",
        "Mental Disorders",
        "Mood Disorders",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-11-06",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511908"
    },
    {
      "nct_id": "NCT00167310",
      "title": "Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Major Depression",
        "Bipolar Disorder",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Eicosapentaenoic acid (omega-3 fatty acid)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2005-09",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167310"
    },
    {
      "nct_id": "NCT00163059",
      "title": "The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "NMDA Antagonist, CP-101,606 (traxoprodil)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-05",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2006-09-22",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Wichita, Kansas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00163059"
    },
    {
      "nct_id": "NCT00963196",
      "title": "Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Omega-3 fatty acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Bovine gelatin capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2009-09",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2010-06-04",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963196"
    },
    {
      "nct_id": "NCT07076342",
      "title": "The Role of mGluR5 in CBT-I",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder (MDD)"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy for Insomnia",
          "type": "BEHAVIORAL"
        },
        {
          "name": "PET Scan with [11C]ABP688",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2025-08-01",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076342"
    },
    {
      "nct_id": "NCT00581009",
      "title": "The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "chronobiological augmentation",
          "type": "OTHER"
        },
        {
          "name": "sertraline, lithium",
          "type": "DRUG"
        },
        {
          "name": "one night of sleep deprivation and two FDG PET scans",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 49,
      "start_date": "2001-05-30",
      "completion_date": "2011-12-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 2,
      "location_summary": "Irvine, California • La Jolla, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00581009"
    },
    {
      "nct_id": "NCT01670019",
      "title": "Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder Without Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Asenapine 5-20 mg daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo 1-4 tablets daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2012-10",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-09-03T13:37:38.998Z",
      "location_count": 5,
      "location_summary": "Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670019"
    }
  ]
}